Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Tuesday, September 29, 2026

Snapshot: Sep 29, 2026 · 5:00 PM 50 stocks analyzed

Strong Down Day

Tue, Sep 29, 2026 Broad Selloff High

Broad selloff crushes equities across the board as small caps and tech absorb heaviest losses; Russell 2000 down 2.84%, S&P 500 off 1.21%, with 50 stocks plunging over 25% on hi…

60% A broad market collapse gripped US equities with the Russell 2000 falling 2.84%, S&P 500 down 1.21%, and Nasdaq Composite off 1.64%, driven by a wave of negative corporate news including bankruptcies, reverse splits, dilutive offerings, and failed clinical trials that hit micro-cap and mid-cap names with disproportionate force. High dispersion saw 50 stocks tumble more than 25%, led by KNRX down 58% on a carve-out deal, FWACW warrant warrant down 50% on merger concerns, and AMZE down 41% amid NYSE delisting proceedings. Technology dominated the losers list at 31%, while Healthcare contributed 28%, signaling broad sector capitulation rather than a narrow rotation.
25% Single-stock catastrophe drove the day's high dispersion, with news-grounded collapses including GETY down 41% on distressed financing reports, FICO down 27% after the FHFA announced VantageScore as a mortgage scoring alternative ending FICO's monopoly, QURE down 38% on missed Huntington's disease gene therapy endpoints, and CLPT down 23% on partner uniQure's trial disappointment, while multiple reverse splits and secondary offerings triggered panic selling among retail holders.
15% HUBC extended a six-day losing streak into the top 50 with a 33% drop, while Getty Images' financial distress and a wave of SPAC delisting and redemption pressure on blank-check vehicles created persistent downward momentum in speculative corners of the market, though broad uncertainty over many micro-cap moves hints that technical selling and liquidity constraints may be amplifying the damage beyond fundamental disappointment.

Technology drove 31% of losers HUBC on a 6-day losers streak 5 names returned after long absences HUBC · 6-day losers streak GETY · 4-day losers streak SANG — first appearance

Market Regime

Tue, Sep 29, 2026 Neutral conf: medium macro · prototype

-2

Neutral −100 … +100 · + tailwind / − headwind

VIX16.0 p40 Drawdown-1.6% Held5d · building SinceSep 23

Top drivers: Small-cap leadership ▼ VIX percentile ▲ S&P drawdown (60d) ▲

processId: history-market-regime

Market Indexes

Tue, Sep 29, 2026 13

S&P 500

7,670.84

−93.80

-1.21%

Dow Jones

51,349.92

−513.77

-0.99%

NASDAQ Composite

26,797.54

−446.74

-1.64%

NASDAQ 100

30,339.33

−393.07

-1.28%

DJ US Total Market

75,576.02

−1,030.24

-1.34%

Russell 1000

4,167.00

−54.49

-1.29%

S&P MidCap 400

3,618.47

−56.63

-1.54%

Russell 2000

2,807.92

−82.00

-2.84%

Russell 2500

1,206.13

−1.93

-0.16%

Russell 3000

4,339.32

−59.52

-1.35%

Nasdaq Financial-100

7,293.15

−49.37

-0.67%

NIFTY 50

22,716.20

−730.60

-3.12%

VIX

16.04

+0.86

+5.67%

Biggest Gainers

Tue, Sep 29, 2026 50

BKYI

Bio-key International IncIndustrials

$3.13+$1.43

+83.6%

HEPA

Hepion Pharmaceuticals IncHealthcare

$0.10+$0.04

+55.5%

DXST

Decent Holding Inc Ordinary SharesIndustrials

$3.04+$1.08

+54.8%

EVGN

Evogene LtdHealthcare

$0.40+$0.22

+54.8%

JONER

Jones Ventures INTL Acquisition1 Corp

$0.15+$0.05

+49.9%

SSTI

ShotSpotter IncTechnology

$8.22+$2.72

+49.5%

BGIN

Bgin Blockchain LimitedTechnology

$2.54+$0.80

+43.2%

FIXX

Homology Medicines Inc

$13.13+$3.90

+42.3%

SVRN

OceanPal Inc.Industrials

$67.58+$20.74

+41.7%

COPL.WT

Copley Acquisition Corp WT

$0.04+$0.01

+39.1%

MSGY

Masonglory LimitedIndustrials

$4.44+$1.35

+38.7%

SANG

Sangoma Technologies Corporation Common Shares

$4.92+$1.37

+38.5%

FCRS.WT

FutureCrest Acquisition Corp. WT

$0.70+$0.19

+38.0%

IOVA

Iovance Biotherapeutics IncHealthcare

$14.45+$3.47

+31.6%

ARCLR

ARC Group Acquisition I Corp Right

$0.17+$0.04

+30.7%

OYSER

Oyster Enterprises II Acquisition Corp Rights

$0.12+$0.03

+30.4%

SLXN

Biomotion SciencesHealthcare

$0.32+$0.07

+29.4%

EJH

E-Home Household Service Holdings LimitedConsumer Cyclical

$1.54+$0.33

+27.4%

TJGC

TJGC Group LimitedCommunication Services

$36.76+$7.86

+27.2%

UYSCR

UY Scuti Acquisition Corp.

$0.14+$0.03

+27.1%

SMJF

SMJ International Holdings Inc.Consumer Cyclical

$2.64+$0.55

+26.8%

LONA

Leonabio Inc

$3.56+$0.74

+26.2%

SLE

Super League Gaming IncCommunication Services

$5.63+$1.11

+24.6%

WYY

WidePoint CorpTechnology

$7.28+$1.44

+24.6%

ONEN

Hennessy Capital Investment Corp. VII

$2.63+$0.49

+22.9%

APACR

StoneBridge Acquisition II Corporation Rights

$0.11+$0.02

+22.1%

AIFU

Fanhua Inc.Financial Services

$10.84+$1.94

+21.8%

BNCWW

CEA Industries Inc. WarrantIndustrials

$0.02+$0.00

+21.0%

NAUT

Nautilus Biotechnology, Inc.Healthcare

$1.36+$0.24

+20.9%

WTER

Alkaline Water Co Inc-TheConsumer Defensive

$0.02+$0.00

+20.6%

QSI

Quantum-Si incorporated

$0.97+$0.17

+20.6%

Missfresh LimitedCommunication Services

$16.95+$2.88

+20.5%

PEW.WT

GrabAGun Digital Holdings Inc. WT

$0.30+$0.05

+20.0%

OIO

OIO GroupIndustrials

$1.72+$0.29

+19.9%

MGRX

Mangoceuticals, Inc. - Common StockHealthcare

$0.45+$0.07

+19.1%

CHARR

Charlton Aria Acquisition Corporation Rights

$0.10+$0.02

+19.0%

CELG.RI

Bristol-Myers Squibb Company Ce

$0.12+$0.02

+19.0%

CAPS

Capstone Therapeutics CorpBasic Materials

$0.15+$0.03

+18.7%

INACR

Indigo Acquisition Corp. Right

$0.12+$0.02

+18.5%

PLUT

Plutus Financial Group Limited Ordinary SharesFinancial Services

$2.50+$0.39

+18.5%

EEIQ

Elite Education Group International LimitedConsumer Defensive

$5.60+$0.79

+16.4%

SLND

Southland Holdings, Inc.Industrials

$0.69+$0.10

+15.9%

TEAD

Teads B.V.Communication Services

$0.51+$0.07

+15.9%

COSM

Cosmos Holdings Inc.Healthcare

$0.42+$0.06

+15.9%

NEXR

Nexera Technologies Ltd.Consumer Cyclical

$1.78+$0.24

+15.6%

ITG

ITG, Inc.Industrials

$8.16+$1.10

+15.5%

XRPN

Armada Acquisition Corp. II

$12.90+$1.72

+15.5%

PFSA

Profusa, Inc.Healthcare

$2.25+$0.27

+15.3%

ZSTK

ZeroStack Corp.Financial Services

$4.90+$0.65

+15.2%

DNA

Ginkgo Bioworks Holdings, Inc.

$11.97+$1.52

+14.5%

Biggest Losers

Tue, Sep 29, 2026 50

KNRX

KNOREX LTD.Technology

$0.35−$0.50

-58.3%

NYSE · Mkt cap $10 M

KNOREX announced a strategic carve-out of its AscendX Publisher Monetization Business with external growth capital on September 28, which likely triggered the 58% stock price collapse due to shareholder concerns about dilution, loss of a key revenue asset, or negative market interpretation of the…

The single headline available confirms that KNOREX announced a major strategic transaction involving the separation of AscendX, described as a "publisher monetization business," paired with external capital investment. This type of announcement typically triggers sharp downside moves when the market perceives dilution to existing shareholders, a loss of competitive advantage, or unfavorable deal terms. The fact that the carve-out involves bringing in "external growth capital" suggests equity dilution or a loss of control over an important revenue stream. Without access to the full press release details—including the valuation of the carve-out, the dilution percentage, or the strategic rationale—it is difficult to determine whether the market is overreacting or responding rationally. However, a 58% single-day drop indicates severe negative sentiment around the transaction structure or its implications for shareholder value.

FWACW

Futurewave Acquisition Corporation Warrants

$0.02−$0.02

-50.0%

AMZE

Fresh Vine Wine, Inc.Technology

$0.07−$0.05

-41.1%

NYSE · Mkt cap $1.5 M

NYSE American commenced delisting proceedings against AMZE on the same day the company announced a $155 million reverse acquisition deal, triggering a sharp 41% sell-off as investors reacted to the dual negative of regulatory action and dilutive equity financing.

The 41% drop on 2026-09-29 appears directly tied to the NYSE American delisting announcement released at 20:01 UTC, which would have been the final catalyst after market hours or driven pre-market selling. The company had announced earlier that day a binding letter of intent for an all-stock acquisition of BullionFX's Alchemy platform valued at $155 million. While reverse acquisitions and pivot strategies (from creator economy to gold-backed DeFi) typically carry execution risk, the delisting threat is the more immediate shock to equity holders, as it threatens the stock's exchange listing and liquidity. The all-stock deal structure also implies significant shareholder dilution. The delisting proceeding alone would justify a material decline in a micro-cap stock trading at $0.07, where listing status directly affects tradability and investor access.

GETY

Getty Images Holdings, Inc.Communication Services

$0.08−$0.06

-40.6%

NYSE · Mkt cap $111 M

Getty Images plunged 40.62% after Bloomberg reported the company is in confidential talks with lenders about rescue financing, possibly including a debtor-in-possession loan, signaling severe financial distress.

The headline from September 28 directly establishes that Getty Images is in talks with lenders about new financing through what may be a DIP loan, a financing structure typically used by companies in or near bankruptcy. This type of announcement signals to the market that the company's financial position has deteriorated materially and that management believes traditional financing is unavailable. The stock's position as the fourth-biggest loser of the day, combined with the magnitude of the decline, is consistent with investor interpretation of distressed financing discussions as a precursor to restructuring or bankruptcy. The second headline about consumer stocks being mixed is sectoral context and does not explain GETY's specific move. No competing explanations (earnings beat, strategic wins, regulatory approvals) are present in the provided news.

DCX

Chijet Motor Company, Inc.Consumer Cyclical

$3.61−$2.38

-39.3%

NASDAQ · Mkt cap $322 M

DCX announced a 1-for-160 reverse stock split scheduled for September 28, 2026, which typically signals financial distress and dilution concerns, likely triggering the 39% single-day drop.

The provided headline confirms DCX executed a 1-for-160 reverse stock split on September 28, the same day this price drop occurred. Reverse splits are mechanically neutral to shareholder value but are widely interpreted by markets as a red flag, typically associated with companies trying to regain NASDAQ compliance (minimum price thresholds) or manage severe stock price deterioration. The headline also mentions a recently completed $5.0 million follow-on offering, which compounds dilution concerns. While the mechanical reverse split itself does not change ownership percentages, the market interpretation—that a company has become distressed enough to require such action—often triggers significant selling pressure. The timing between the September 28 split announcement and the September 29 price drop is consistent with post-announcement selling. However, the headline text appears truncated, limiting visibility into whether additional negative catalysts were disclosed.

AIXC

Aixcrypto Holdings IncTechnology

$1.01−$0.63

-38.4%

QURE

uniQure NVHealthcare

$24.45−$14.68

-37.5%

TWLVR

Twelve Seas Investment Company III Rights

$0.08−$0.04

-37.2%

NASDAQ

No news was published in the last 48 hours, but the -37% drop in this SPAC rights offering is likely driven by expiring redemption deadlines, broader SPAC redemption pressure, or deteriorating merger negotiations for the underlying blank-check company.

Twelve Seas Investment Company III Rights is a SPAC rights instrument, a security with inherent structural dynamics that differ from ordinary equities. Rights offerings on SPACs typically face value compression as redemption deadlines approach, since shareholders redeeming their shares often exercise or abandon associated rights. The absence of any news headlines in the last 48 hours suggests the move was not triggered by a specific announced event, earnings, or deal update. However, this does not mean the cause is unknowable. SPAC rights commonly experience sharp declines during windows when redemption deadlines loom, when the underlying merger remains uncertain, or when the broader SPAC market faces headwinds. The rank as the 8th biggest loser indicates this was a market-wide washout day for such instruments rather than a company-specific announcement.

RETO

Reto Eco-solutions IncBasic Materials

$0.09−$0.05

-35.6%

NASDAQ · Mkt cap $13 M

ReTo announced a 20-to-1 share consolidation approved by its board, which typically signals financial distress and dilution concerns, likely driving the 35.62% single-day sell-off.

The company announced a twenty-to-one share consolidation, a reverse split that reduces the number of outstanding shares while proportionally adjusting per-share value. This type of corporate action is commonly undertaken when a stock trades at extremely low prices and risks delisting, or when management seeks to improve the stock's optics. Market reaction to reverse splits is typically negative because they signal underlying financial weakness, do not create fundamental value, and often precede additional shareholder dilution or restructuring. Investors frequently view such announcements as red flags rather than positive developments, regardless of stated rationale. The sharp 35.62% decline on the announcement day reflects this standard negative market interpretation of reverse-split news, especially for micro-cap stocks trading at penny levels.

HUBC

Hub Cyber Security Ltd. - Ordinary SharesTechnology

$0.99−$0.49

-32.8%

NASDAQ · Mkt cap $23 M

No headlines were found in the last 48 hours, so the cause of the 32.78% decline cannot be confirmed from news sources; the drop likely stems from a company announcement, earnings release, or market event not yet reflected in the available news feed.

Without recent headlines in the provided news data, the specific trigger for HUBC's sharp 32.78% decline remains unexplained by the information at hand. For a cybersecurity company trading at $0.99, typical catalysts for such steep losses include disappointing earnings or revenue guidance, loss of a major customer or contract, executive departures, regulatory setbacks, competitive pressures, or dilutive financing announcements. Given that HUBC is ranked as the tenth biggest loser of the day, the move is material enough to suggest a company-specific event rather than pure market-wide weakness. It is also possible that news was released after market open and has not yet propagated to the Yahoo Finance RSS feed used here, or that the catalyst was disclosed via press release or SEC filing before the headline aggregation.

JLHL

Julong Holding LimitedIndustrials

$4.05−$1.86

-31.5%

NASDAQ · Mkt cap $152 M

Julong announced a private placement on September 28, which typically signals dilution concerns and triggered a 31.49% selloff, making it the 11th biggest loser on the day.

The company announced a private placement, a corporate action that usually causes immediate market pressure due to shareholder dilution concerns. Private placements involve issuing new shares at a negotiated price, often below market value, to raise capital quickly. Investors typically discount stocks sharply upon such announcements because existing shareholders face reduced ownership percentage and potential downward price pressure from the newly issued shares entering the market. The headline was truncated and provided no details on the offering size, price, or use of proceeds, so the severity of dilution cannot be quantified from the available information. However, the magnitude of the decline suggests the market reacted negatively to the announcement itself, which is the standard response to dilutive capital raises in this sector.

BYSI

Beyondspring IncHealthcare

$0.77−$0.35

-31.0%

NASDAQ · Mkt cap $30 M

BeyondSpring announced FDA Fast Track designation for Plinabulin and a strategic transaction to advance its Phase 3 trial, yet the stock fell 31% despite this positive regulatory news, suggesting investors reacted negatively to the financing or partnership terms rather than the clinical milestone…

The headlines disclose two corporate events on 2026-09-29: FDA Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC (a genuine regulatory win that typically supports stock valuations), and a "strategic transaction designed to reduce cash required" to advance the global Phase 3 DUBLIN-4 trial. While Fast Track status is favorable for clinical and regulatory timelines, the market's 31% decline suggests the strategic transaction—likely a dilutive financing, partnership with unfavorable economics, or asset sale—outweighed the regulatory positive. The incomplete disclosure of transaction details in the headlines limits certainty, but biotech investors typically punish equity raises or partnerships that dilute shareholder value more heavily than they reward clinical progress, particularly in late-stage development where capital raises are common. The severity of the drop (rank 12 largest loser) indicates material concern about the transaction structure or its cost to equity holders.

ILLR

Triller Group Inc.Technology

$0.24−$0.11

-30.7%

NASDAQ · Mkt cap $20 M

No news headlines were available in the last 48 hours for Triller Group, so the 30.7% single-day drop cannot be directly attributed to a specific catalyst based on the evidence provided. The decline likely reflects broader market dynamics, technical selling, or undisclosed developments.

The absence of any Yahoo Finance headlines in the past two days makes it impossible to point to a concrete news catalyst for ILLR's sharp 30.7% decline. Triller Group is a volatile microcap stock trading near $0.24, which typically exhibits high price swings on relatively low volume and can be sensitive to sentiment shifts, short-seller activity, insider trading patterns, or broader sector weakness in social media or entertainment technology. Without access to real-time news, SEC filings, or trading volume data, the specific trigger remains unknown. Possible categories include delayed earnings disappointment, liquidity concerns, share dilution announcements, or purely technical/sentiment-driven selling, but these are speculative rather than evidence-based.

SSEAR

Starry Sea Acquisition Corp Rights

$0.07−$0.03

-29.9%

EPOW

$3.76−$1.45

-27.8%

COLAR

Columbus Acquisition Corp Rights

$0.28−$0.11

-27.3%

FICO

Fair Isaac CorpTechnology

$616.86−$223.99

-26.6%

NYSE · Mkt cap $21 B

Fair Isaac plunged 26.64% after the Federal Housing Finance Agency announced it will introduce VantageScore as a competitor to FICO's mortgage credit scoring, effectively ending FICO's near-monopoly in mortgage pricing and threatening a major revenue stream.

The headlines establish a clear, material catalyst. On September 29, 2026, FHFA Director Bill Pulte announced that Fannie Mae and Freddie Mac will merge their mortgage pricing grids into a single grid that incorporates VantageScore alongside FICO Classic. Multiple sources confirm this is the first meaningful competition FICO has faced in mortgage lending, a business segment that has historically been a dominant profit driver. The stock fell approximately 27% intraday, marking its worst day since 1989 according to one headline. This represents investor repricing of FICO's long-term competitive moat and earnings power. One headline notes this comes amid broader headwinds including AI-related pressures, though the government's action is clearly the primary catalyst for today's collapse. The shift is attributed to the Trump administration's focus on reducing monopolistic advantages in financial services.

NCT

Intercont (Cayman) Limited Ordinary sharesIndustrials

$1.87−$0.72

-26.6%

NASDAQ · Mkt cap $38 M

No news headlines were found in the last 48 hours for NCT, so the 26.57% drop cannot be attributed to any reported event. The cause likely stems from technical selling, market sentiment shift, or an untracked announcement.

The absence of recent news makes it difficult to pinpoint a specific catalyst for this large single-day decline. NCT (Intercontinental) is a thinly traded offshore holding company listed on NASDAQ, and such securities are particularly susceptible to sudden moves driven by technical factors, liquidity events, or small-volume sell-offs that can create outsized percentage moves. Possible explanations include: first, a delayed earnings miss or guidance warning that may not yet be widely distributed through major news feeds; second, a regulatory or compliance concern specific to Cayman Islands-domiciled entities; third, simple technical selling or algorithmic liquidation in a low-liquidity name. Without headline evidence, the true driver remains opaque.

PMAX

Powell Max Limited Class A Ordinary SharesFinancial Services

$0.91−$0.32

-26.0%

NASDAQ · Mkt cap $2.1 M

Powell Max announced a minority stake acquisition in Blackrod Holdings (parent of Remington Firearms) with a 12-month exclusivity deal, but the market sold off 26% likely due to concern over execution risk, valuation, or the firearms sector exposure itself.

Powell Max announced on September 28 that it acquired a minority stake in Blackrod Holdings and secured an exclusive 12-month period to negotiate full majority acquisition of the Remington Firearms business. The news was released in two near-identical press releases within two hours. While the headlines describe the deal structure, they do not disclose valuation, financing details, or strategic rationale. The sharp 26% single-day drop suggests investor skepticism about the transaction. Possible explanations include concern over acquisition price and funding structure, reputational or operational risks associated with the firearms industry, doubt about Powell Max's ability to execute the majority acquisition within 12 months, or general market concern about dilution or debt. Without detail on terms or financial impact, the exact driver remains unclear, but the market's reaction is notably negative relative to what appears to be a strategic initiative.

ONCO

Onconetix, Inc.Healthcare

$0.82−$0.29

-25.7%

NASDAQ · Mkt cap $2.8 M

No headlines were published in the last 48 hours, so the cause of the 25.68% drop cannot be determined from the provided news sources. The sell-off may reflect sector weakness, company-specific concerns, or technical trading activity.

The absence of news headlines in the last 48 hours is notable given the magnitude of the decline. For a small-cap biotech or oncology stock like Onconetix trading at $0.82, large single-day moves often correlate with clinical trial results, regulatory setbacks, financing announcements, or insider activity. The lack of a reported catalyst suggests the move may be driven by technical factors such as stop-loss selling, short covering reversal, or broader market weakness in the biotech sector. Alternatively, news may have been released through channels not captured in the Yahoo Finance RSS feed, or the decline could reflect delayed market reaction to an earlier announcement. Without access to earnings reports, SEC filings, or company press releases from the relevant period, the specific catalyst remains unknown.

KPTI

Karyopharm Therapeutics IncHealthcare

$1.21−$0.42

-25.6%

NASDAQ · Mkt cap $45 M

No news headlines were found in the last 48 hours, so the 25.55% drop likely stems from a clinical, regulatory, partnership, or financial development that has not yet appeared in the RSS feed, or from general biotech sector weakness affecting smaller-cap names.

Karyopharm is a clinical-stage biopharmaceutical company whose stock typically moves on clinical trial results, FDA regulatory decisions, financing announcements, or partnership news. The absence of any headlines in the last two days despite a sharp 21st-ranked decline suggests either a news event has occurred but not yet been picked up by Yahoo Finance RSS, or the decline reflects a delayed market reaction to a recent announcement, sector rotation away from biotech, or negative sentiment in the small-cap therapeutic space. Without concrete evidence, the most probable categories are a clinical setback, financing dilution, regulatory disappointment, or broad index pressure on early-stage life sciences stocks. The timing and magnitude warrant checking primary sources like the company's press releases or the NASDAQ tape directly.

CUEN

Cuentas Inc.Technology

$0.49−$0.16

-24.4%

NASDAQ · Mkt cap $5.4 M

No news headlines are available for CUEN in the last 48 hours, so the 24% drop likely reflects either a delayed market reaction to an untracked announcement, technical selling, or sector-specific headwinds affecting micro-cap stocks.

The absence of any headlines in the Yahoo Finance RSS feed over the past 48 hours makes it impossible to identify a specific catalyst for the 24.36% decline. This is not uncommon for micro-cap stocks trading below $1, which often experience higher volatility and receive less consistent news coverage. The drop could stem from several possibilities: a company-specific announcement that has not yet been widely reported, sector rotation affecting smaller-cap equities, technical breakdown through support levels common in penny stocks, or a delayed market reaction to an older development. Without access to company filings, press releases, or trading halt information, we cannot determine whether this move reflects fundamental deterioration, technical capitulation, or simply low liquidity amplifying a minor trader exodus.

WETO

Webus International Limited Ordinary SharesTechnology

$1.09−$0.40

-24.1%

XHLD

TEN Holdings, Inc. Common StockCommunication Services

$0.75−$0.23

-23.4%

NASDAQ · Mkt cap $92 M

No news headlines were found in the last 48 hours, so the 23.4% drop cannot be attributed to a specific announced event; the cause remains unclear without additional context or market data.

The absence of recent news headlines makes it difficult to pinpoint a concrete reason for TEN Holdings' sharp 23.4% decline on September 29, 2026. Stocks in this price range and market cap tier can be sensitive to various catalysts including broader market selloffs, sector rotation, technical support breaks, or undisclosed company developments not yet picked up by major news feeds. Penny stocks and microcap names are also prone to higher volatility and lower liquidity, which can amplify single-day moves. Without earnings announcements, regulatory actions, partnership news, or other identifiable catalysts in the headline record, the drop could reflect general market conditions, short covering, or information not yet indexed by public financial news services.

AIIOW

NWTN Inc. WarrantConsumer Cyclical

$0.01−$0.00

-23.3%

CITR

General Enterprise Ventures, Inc.Basic Materials

$2.89−$0.88

-23.2%

NYSE

No news headlines were published in the last 48 hours for CITR, so the 23.24% drop cannot be directly attributed to a disclosed event; the decline is likely due to technical selling, sector weakness, or undisclosed market sentiment.

The absence of news in the recent headlines makes it difficult to pinpoint a specific catalyst for CITR's sharp 23.24% decline. General Enterprise Ventures is a small-cap stock, and securities in this category are often sensitive to broad market movements, sector rotation, or technical factors rather than company-specific announcements. Possible explanations include broader market weakness affecting micro-cap stocks, a shift in investor sentiment toward technology or venture-related securities, accumulation of short positions ahead of an anticipated announcement or earnings date, or simply a rebalancing by holders. Without accompanying news or context, we cannot distinguish between these scenarios based on the available evidence alone.

CLPT

ClearPoint Neuro IncHealthcare

$11.76−$3.56

-23.2%

NASDAQ · Mkt cap $487 M

ClearPoint Neuro shares fell 24% following updated clinical trial results from partner uniQure N.V. regarding the AMT-130 program, suggesting the trial update was materially negative or disappointing to investors.

The headline directly links the 24% intraday drop to an updated clinical trial result from uniQure's AMT-130 program. ClearPoint appears to have a partnership or technology involvement with uniQure on this trial. The magnitude of the decline and its immediate timing suggest the trial update contained adverse efficacy data, safety concerns, or missed primary endpoints that materially reduced investor confidence in the program's commercial prospects. The news does not specify which aspect of the trial disappointed, but the market's swift reaction indicates the update was meaningfully negative rather than neutral or modestly positive. Without the full text of the trial results, the precise nature of the setback cannot be confirmed, but the timing and magnitude are consistent with failed or significantly underwhelming clinical trial news for a biotech-adjacent company.

ELAB

Elevai Labs, Inc.Healthcare

$3.67−$1.11

-23.2%

NASDAQ · Mkt cap $2.5 M

A partnership announcement naming NorthStrive Biosciences and Charles River Laboratories appears unrelated to ELAB; the 23% drop likely stems from a negative catalyst within ELAB itself that is not captured in the provided headlines.

The only news item provided references NorthStrive Biosciences partnering with Charles River Laboratories on programs EL-22 and EL-32, but the headline does not mention Elevai Labs (ELAB) by name or indicate that NorthStrive is ELAB or a subsidiary. This creates ambiguity: either NorthStrive is a separate entity, in which case the headline is unrelated to ELAB's 23% intraday loss, or there is a connection not made explicit in the headline text provided. Absent clarity on that link, the drop appears driven by something else—potentially negative clinical trial results, withdrawn guidance, insider selling, broader sector decline, or analyst downgrades affecting small-cap biotech names. The magnitude and ranking as 28 biggest loser suggest a company-specific event rather than market-wide weakness.

AZTR

Azitra Inc Common StockHealthcare

$0.13−$0.04

-23.1%

NYSE · Mkt cap $2.0 M

AZTR fell 23% on a research valuation update issued September 28th reflecting reassessment of its cosmetic and EGFRi rash programs, likely indicating downward valuation revision or reduced pipeline confidence.

The only headline provided is a valuation update from September 28th that references cosmetic and EGFRi rash programs and mentions the company's Q2 2026 results from August 12th. The headline is truncated and does not explicitly state whether the valuation was raised or lowered, but the 23% single-day drop the following day suggests the research conclusion was materially negative. For a small biotech stock like AZTR with limited liquidity, a major research firm's valuation cut on clinical programs could easily trigger sharp selling. However, the headline is incomplete and does not specify the actual valuation change, the rationale for revision, or whether any clinical setbacks were cited. Without the full report text, we cannot definitively attribute the move to specific trial data, competitive concerns, or methodology changes.

SOBR

SOBR Safe, Inc.Technology

$0.07−$0.02

-22.2%

NASDAQ · Mkt cap $1.6 M

SOBR dropped 22% with no news reported in the last 48 hours, suggesting the decline was driven by technical selling, a delayed negative announcement, or broad micro-cap weakness rather than a specific disclosed event.

The absence of any headlines in the 48-hour window preceding this 22% intraday loss makes it impossible to attribute the move to a specific catalyst. SOBR is a micro-cap stock trading at $0.07, a price point typically associated with extreme volatility, limited liquidity, and susceptibility to retail trading swings. The drop could reflect several common drivers in this category: technical breakdown below a support level, accumulation of negative sentiment from an earlier announcement now trickling through to late traders, insider selling pressure, or a rumor circulating on social media or message boards that does not yet appear in mainstream financial news feeds. Without disclosed news, we cannot rule out that the stock was simply caught in a broad micro-cap sell-off or experienced a margin call wave. The lack of reported headlines does not prove no material event occurred, only that it is not yet visible in the Yahoo Finance RSS feed used here.

CCG

Cheche Group Inc. - Class A Ordinary SharesCommunication Services

$7.56−$2.14

-22.1%

NASDAQ · Mkt cap $34 M

No news headlines were found in the last 48 hours, so the 22% drop cannot be directly attributed to a disclosed catalyst. The decline may reflect sector weakness, technical selling, or undisclosed company developments.

The absence of recent news makes it impossible to pinpoint a specific cause for CCG's sharp 22% decline on this date. Without earnings reports, guidance changes, regulatory actions, or other disclosed events in the headline feed, we can only speculate about the likely trigger. For a smaller-cap equity like this, sharp single-day drops of this magnitude often reflect either broad-based sector selloffs if CCG operates in a cyclical industry, technical momentum breaks or forced liquidations in options or leveraged positions, delayed disclosure of material adverse news not yet picked up by RSS feeds, or short-squeeze reversal if the stock had been heavily shorted. Without the underlying fundamentals of the business or broader market context, assigning confidence to any single hypothesis is not warranted.

AMSS

AMASS Brands Inc.Consumer Defensive

$0.44−$0.12

-21.9%

NASDAQ · Mkt cap $11 M

AMASS Brands reported strong electrolyte product momentum with $1.4 million annualized revenue run rate and September sales approaching double August levels, yet the stock fell 21.88%, suggesting the market either expected larger gains, has concerns about profitability or cash burn, or reacted to…

The headline announced genuinely positive operational progress: the electrolytes product line reached approximately $1.4 million in annualized revenue run rate just four months post-launch, with September bookings nearly doubling August levels and distributor partnerships expanding to six U.S. markets. This is objectively bullish product traction. However, the stock dropped sharply, which creates a disconnect. The most likely explanations are: first, market disappointment if investors had priced in even larger numbers based on earlier guidance or analyst expectations; second, concern about unit economics, cash burn rate, or path to profitability despite top-line growth, which is common for early-stage consumer brands; third, the announcement itself may have triggered profit-taking in a volatile micro-cap stock; or fourth, external market factors or undisclosed news unrelated to this press release drove the decline. Without forward guidance, profitability metrics, or broader context on investor expectations, the disconnect between the news content and price action remains unexplained by the headline alone.

FEED

ENvue Medical, Inc.Healthcare

$0.30−$0.08

-21.5%

NASDAQ · Mkt cap $3.9 M

No news headlines appeared in the last 48 hours, so the 21.49% drop in FEED stock cannot be directly attributed to a disclosed event. The move likely reflects either delayed market reaction to prior news, technical selling, or broader market sentiment toward the microcap medical device sector.

With no recent headlines available to explain the sharp decline, the cause remains opaque from a news-driven perspective. ENvue Medical trades at a low share price typical of development-stage or struggling medical device companies, which are generally sensitive to liquidity conditions, institutional selling, or negative sentiment shifts even without announced catalysts. Possible explanations include: first, a delayed market reaction to earnings, clinical trial results, or operational updates released outside the 48-hour window; second, profit-taking or forced liquidation by a key holder; third, sector-wide pressure on small-cap medtech stocks. Without concrete headlines, attribution remains speculative.

APUS

Apimeds Pharmaceuticals US, IncHealthcare

$4.96−$1.35

-21.4%

LHSW

Lianhe Sowell International Group Ltd Ordinary SharesTechnology

$0.53−$0.14

-20.9%

NASDAQ · Mkt cap $9.6 M

No news headlines were found in the last 48 hours, so the 20.89% drop cannot be attributed to any disclosed event. The decline was likely driven by technical selling, market sentiment, or unannounced developments.

The absence of recent news headlines makes it impossible to identify a specific catalyst for this sharp 20.89% decline in LHSW stock. Given that this is a relatively illiquid micro-cap security trading at $0.53, price movements of this magnitude can be driven by several factors: technical selling or stop-loss triggers, shifts in sector sentiment, unexpected insider transactions or regulatory filings not yet reflected in standard news feeds, rumor or social media activity, or simple rebalancing by holders. Stocks at this price point and market capitalization are also more susceptible to volatility unrelated to company fundamentals. Without corroborating headlines or SEC filings data, the specific cause remains speculative.

TDIC

Dreamland LimitedCommunication Services

$2.11−$0.57

-20.6%

NASDAQ · Mkt cap $4.0 M

No news headlines were available in the past 48 hours to explain the 20.57% drop in TDIC stock, so the cause remains unclear without additional context or market data.

The absence of any headlines in the Yahoo Finance RSS feed over the last 48 hours means we cannot point to a specific catalyst such as earnings, regulatory action, partnership news, or guidance revision. A 20.57% single-day decline for a stock trading at $2.11 is substantial and typically warrants a material trigger. Possible explanations in the absence of news could include broader market selloff affecting micro-cap or penny stocks, a delayed announcement or filing not yet picked up by major news sources, technical breakdown driven by stop-loss orders, short seller activity, or sector-wide pressure. Without access to the full trading context, market sentiment, or company-specific developments, determining the root cause requires additional information beyond what the headlines provide.

FSHPR

Flag Ship Acquisition Corporation

$0.09−$0.02

-20.4%

NASDAQ

No news headlines were found in the last 48 hours, so the 20% drop likely reflects either technical selling pressure, sector rotation, or undisclosed developments specific to this blank-check acquisition company.

Flag Ship Acquisition Corporation is a special purpose acquisition company (SPAC) trading at $0.09 with no recent news to explain today's sharp 20.38% decline. SPACs typically trade near their $10 cash redemption value or collapse when deal certainty erodes. At this price, the stock is deeply underwater, suggesting either that a proposed merger has failed or been abandoned, that warrant redemptions are occurring, or that market sentiment has shifted against the deal. Without confirmed headlines, the most likely categories are a delayed announcement about deal termination, regulatory obstacles to a pending merger, or redemption pressure from shareholders losing patience. The absence of news does not rule out private developments that markets may be pricing before public disclosure.

JACS.RI

Jackson Acquisition Company II

$0.04−$0.01

-20.0%

ATXI

Avenue Therapeutics IncHealthcare

$0.40−$0.10

-20.0%

NASDAQ · Mkt cap $824 K

No news headlines were available in the last 48 hours to explain ATXI's 20% decline, so the cause remains unclear without access to broader market context or company-specific information on September 29.

Avenue Therapeutics is a small-cap biopharmaceutical company, and the absence of recent news headlines makes it difficult to pinpoint the specific catalyst for today's 20% drop. Small biotech stocks are typically sensitive to clinical trial results, regulatory decisions, financing announcements, or changes in cash runway expectations. Without confirmed news, the decline could reflect a delayed market reaction to an earlier announcement, sector-wide weakness in biotech, deteriorating fundamentals revealed through a filing not yet picked up by major news feeds, or technical selling pressure. For a company trading at $0.40, individual contract wins or losses, partnership news, or capital raise necessity often drive outsized moves. The lack of available headlines suggests either the catalyst was not material enough for major coverage, occurred through a company filing rather than a press release, or represents technical/sentiment-driven selling in a lower-liquidity stock.

CLAQ

CleanTech Acquisition Corp.

$1.86−$0.46

-19.8%

FUSE

Fusion Acquisition CorpTechnology

$0.55−$0.13

-19.7%

NYSE · Mkt cap $24 M

FUSE dropped 19.75% on moderate trading volume with no negative news; the positive AI infrastructure announcement from Fusemachines suggests either profit-taking after a prior run, market indifference to the development deal, or an unrelated catalyst not captured in the available headlines.

The single headline is positive—Fusemachines gained access to IBM infrastructure at nominal cost to accelerate AI Twin development. This type of announcement typically supports equity value rather than triggering a 19.75% drop. For a SPAC or blank-check acquisition vehicle like Fusion Acquisition Corp, the likely explanations are market-wide SPAC selloff sentiment, profit-taking on earlier gains, deteriorating sentiment toward the AI sector despite positive company news, redemption pressure if shareholders view the Fusemachines deal unfavorably, or a catalyst entirely separate from the publicly available headlines. Without knowledge of FUSE's ownership structure, redemption announcements, or broader SPAC indices, it is difficult to pinpoint whether this is company-specific, sector-specific, or technical in nature.

LTCH

Latch, Inc.Technology

$0.16−$0.04

-19.7%

NASDAQ · Mkt cap $31 M

No news headlines appeared in the last 48 hours, so the 19.7% drop cannot be directly attributed to a specific company announcement; the decline may reflect broader market conditions, technical selling, or unannounced developments not yet captured in major financial media.

Latch is a hardware and software company focused on smart access control and multifamily housing technology, a sector that can be sensitive to real estate cycles, investor sentiment, and liquidity conditions. The stock's sharp single-day decline without accompanying headlines in major news feeds suggests either a delayed market reaction to developments not yet widely reported, technical selling pressure, sector-wide weakness in the residential technology or proptech space, or a liquidity event affecting the stock price. The stock's low absolute price of $0.16 also makes it potentially more volatile and subject to large percentage swings on modest share volume. Without concrete news, the specific trigger remains unclear.

OPTT

Ocean Power Technologies IncIndustrials

$1.35−$0.32

-19.4%

NYSE · Mkt cap $52 M

No headlines were reported in the last 48 hours for OPTT, so the 19.4% decline cannot be directly attributed to company-specific news. The drop likely reflects broader market conditions, technical selling, or unreported developments.

Ocean Power Technologies is a small-cap renewable energy company with typically low trading volume and high volatility. The absence of any news headlines in the last two days suggests the decline was not driven by announced earnings, contract wins, regulatory decisions, or other major corporate events that would generate press coverage. For stocks of this market capitalization and sector, declines can occur due to several factors: broader market sell-offs in clean energy or small-cap stocks, technical breakdown of support levels triggering algorithmic selling, short-term trader liquidations, or unreported rumors or insider activity that precedes official announcements. Without any substantive news, it is difficult to isolate a specific catalyst, though the magnitude of the single-day drop suggests either technical factors or sentiment-driven selling rather than fundamental deterioration alone.

RYOJ

RYOJBABA CO LTDIndustrials

$3.00−$0.70

-18.9%

NASDAQ · Mkt cap $53 M

No news headlines were found in the last 48 hours for RYOJ, so the 18.92% drop cannot be directly attributed to a reported event. The decline likely stems from technical selling, broader market movement, or unreported company developments.

With no recent news available from Yahoo Finance RSS, the cause of the sharp 18.92% decline in RYOJ cannot be grounded in a specific disclosed event. This presents a challenge in attribution. The stock is ranked 44th among daily losers, suggesting it was not an isolated technical glitch but a genuine sell-off. For smaller-cap international stocks trading on NASDAQ—RYOJ appears to be a Chinese company based on the naming convention—declines without immediate news often reflect several potential drivers: delayed disclosure of earnings or operational results from overseas filings, broader sector rotation out of Chinese equities, margin liquidations, or loss of investor confidence from accumulated negative sentiment. Without access to company filings, regulatory announcements, or social media chatter, the specific trigger remains unknown.

QNC

Quantum eMotion Corp.

$1.75−$0.41

-18.7%

ZZZTT

ETF

$0.82−$0.18

-18.0%

LIQT

LiqTech International IncIndustrials

$0.50−$0.11

-17.9%

NASDAQ · Mkt cap $18 M

No news headlines appeared in the last 48 hours, so the 17.88% drop cannot be directly attributed to a named catalyst. The decline likely reflects either technical selling pressure, delayed market reaction to an earlier announcement, or sector-wide weakness in small-cap stocks.

The absence of recent news makes it impossible to pinpoint a specific catalyst for LIQT's steep single-day decline. LiqTech is a small-cap water and air purification technology company, and stocks in this category can experience outsized volatility from technical factors, short covering, or market-wide liquidations affecting lower-liquidity securities. It is also possible that the stock reacted to news released before the 48-hour window, earnings disappointment, guidance reduction, or competitive developments that were not captured in the Yahoo Finance feed. Without access to company announcements, SEC filings, or social media discussion, determining the root cause remains speculative.

INSE

Inspired Entertainment Inc

$3.28−$0.70

-17.6%

NMTC

NeuroOne Medical Technologies CorporationHealthcare

$1.09−$0.23

-17.4%

NASDAQ · Mkt cap $19 M

No headlines were available in the last 48 hours to explain NMTC's 17.42% drop, so the cause is unknown; possible drivers include sector weakness, technical selling, or undisclosed company developments.

The absence of recent news headlines leaves the cause of this sharp decline opaque. NeuroOne Medical Technologies is a small-cap medical device company, and such stocks are sensitive to multiple factors beyond headline news: sector-wide pressure in medical device or neurotech stocks, profit-taking after prior gains, options expiration effects, insider trading activity, or delayed announcement of clinical trial results or regulatory decisions that may have been disclosed through channels not captured in the RSS feed. Without access to the company's website, SEC filings, or investor relations statements from the snapshot date, it is impossible to determine whether the move was driven by company-specific bad news, market-wide selloff effects, or algorithmic trading patterns. The magnitude of the loss (17.42%) suggests a material negative catalyst rather than routine volatility, but that remains inference rather than established fact.

GITS

Hanryu Holdings, Inc.Communication Services

$1.75−$0.36

-17.1%

NASDAQ · Mkt cap $6.2 M

No news headlines were found in the last 48 hours for GITS, so the 17% drop likely stems from technical selling, sector weakness, or undisclosed company developments not yet captured in major financial media.

The absence of any headlines in the Yahoo Finance RSS feed over the past two days makes it difficult to pinpoint a specific catalyst for the 17.07% decline. GITS is a small-cap stock trading at $1.75 on NASDAQ, which typically means lower liquidity and higher sensitivity to retail sentiment shifts, technical chart breaks, or sector-wide moves in Korean entertainment or consumer stocks. Possible explanations include profit-taking after a recent run, a delayed press release or SEC filing not yet indexed by news aggregators, weakness in the broader Korean entertainment sector that GITS operates in, or accumulation of selling pressure driven by algorithmic trading or changes in fund positioning. Without concrete news, any explanation remains speculative.